TAS4464 hydrochloride

TAS4464 hydrochloride 是一种长效、高选择性、靶向 NEDD8 激活酶 (NAE) 的共价抑制剂 (IC50=0.955 nM),并能抑制 CAII (IC50=0.73 μM,活性低于 MLN4924 (MS-C57164)),其对同为 E1 酶的 UAE 和 SAE 的 IC50 分别为 449 nM 和 1280 nM;它通过以 ATP 依赖的方式靶向 NEDD8 来抑制 NAE,阻断类泛素化修饰 (neddylation) 通路,导致 CRL 泛素连接酶底物 (CDT1、p27、磷酸化 IκBα 等) 累积,进而诱导肿瘤细胞凋亡 (apoptosis),并具有抗增殖和细胞毒作用,对多种血液系统肿瘤和实体肿瘤的细胞系及患者来源肿瘤细胞均表现出广谱抗肿瘤活性,在体内模型中经间歇给药即可显著抑瘤且治疗窗宽、无明显毒性,可用于血液系统肿瘤 (白血病、淋巴瘤、多发性骨髓瘤等) 和实体肿瘤 (小细胞肺癌、结直肠癌、肉瘤、子宫内膜癌、卵巢癌等) 的研究。
产品编号: MS-X07752 纯度: 98.91% CAS No.: 1848959-11-4 分子式: C21H24ClFN6O6S 分子量: 542.97
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

TAS4464 hydrochloride 是一种长效、高选择性、靶向 NEDD8 激活酶 (NAE) 的共价抑制剂 (IC50=0.955 nM),并能抑制 CAII (IC50=0.73 μM,活性低于 MLN4924 (MS-C57164)),其对同为 E1 酶的 UAE 和 SAE 的 IC50 分别为 449 nM 和 1280 nM;它通过以 ATP 依赖的方式靶向 NEDD8 来抑制 NAE,阻断类泛素化修饰 (neddylation) 通路,导致 CRL 泛素连接酶底物 (CDT1、p27、磷酸化 IκBα 等) 累积,进而诱导肿瘤细胞凋亡 (apoptosis),并具有抗增殖和细胞毒作用,对多种血液系统肿瘤和实体肿瘤的细胞系及患者来源肿瘤细胞均表现出广谱抗肿瘤活性,在体内模型中经间歇给药即可显著抑瘤且治疗窗宽、无明显毒性,可用于血液系统肿瘤 (白血病、淋巴瘤、多发性骨髓瘤等) 和实体肿瘤 (小细胞肺癌、结直肠癌、肉瘤、子宫内膜癌、卵巢癌等) 的研究。

生物实验数据

生物活性 TAS4464 hydrochloride is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM) that also inhibits CAII (IC50=0.73 μM, with lower activity than MLN4924 (MS-C57164)), and its IC50 values against the E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively; it inhibits NAE by targeting NEDD8 in an ATP-dependent manner, blocks the neddylation pathway, and causes accumulation of CRL ubiquitin ligase substrates (CDT1, p27, phosphorylated IκBα, etc.), thereby inducing tumor cell apoptosis, and it exhibits antiproliferative and cytotoxic effects with broad-spectrum antitumor activity against various hematological and solid tumor cell lines as well as patient-derived tumor cells, significantly inhibits tumor growth with intermittent dosing in in vivo models with a wide therapeutic window and no obvious toxicity, and can be used for research on hematological tumors (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.).
IC50 & Target NAE:0.955 nM
体外研究
(In Vitro)

TAS4464 hydrochloride 是一种高效且选择性的重组 NAE 抑制剂,对重组 UAE 和 SAE 的选择性分别超过 470 倍和 1340 倍,且对 CA2 的脱靶抑制作用较弱。
TAS4464 hydrochloride (1-10 μM; 24-48 h) 可诱导白血病、淋巴瘤、多发性骨髓瘤及实体瘤细胞系发生凋亡,凋亡率随药物浓度升高而增加。
TAS4464 hydrochloride (1 nM-1 μM, 4 h; 100 nM, 1-24 h) 可显著增加肿瘤细胞中 CRL 泛素连接酶底物 CDT1、p27、磷酸化 IκBα 的蛋白表达水平,同时降低 cullin neddylation 修饰水平。
TAS4464 hydrochloride (0.1-10 μM; 24-48 h) 可显著抑制结直肠癌、肉瘤等实体瘤细胞系的迁移能力,抑制效果呈浓度依赖性。

Cell Viability Assay

Cell Line: Multiple hematologic malignancy cell lines (leukemia, lymphoma, multiple myeloma) and solid tumor cell lines (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer)
Concentration: 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Significantly inhibited the cell viability of various hematologic malignancy and solid tumor cell lines in a concentration- and time-dependent manner.

Western Blot Analysis

Cell Line: Multiple tumor cell lines (hematologic and solid tumor)
Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM
Incubation Time: 6 h, 12 h, 24 h, 48 h
Result: Significantly increased the protein expression levels of CRL ubiquitin ligase substrates (CDT1, p27, phosphorylated IκBα) in tumor cells, and decreased the level of cullin neddylation modification.
体内研究
(In Vivo)

TAS4464 (25-100 mg/kg; i.v.; 每周 2 次; 3 周) hydrochloride 可分别在 T 细胞急性淋巴细胞白血病 (25 mg/kg)、套细胞淋巴瘤 (100 mg/kg)、透明细胞肉瘤 (100 mg/kg)、小细胞肺癌 (75 mg/kg) 等模型中,完全消退肿瘤,同时诱导细胞凋亡,具有较宽的治疗窗口。
TAS4464 (100 mg/kg; i.v.; 第 1, 4, 8, 11 注射, 每 21 天 1 个循坏; 共 8 个循环) hydrochloride 在异植 TMD8-Luc 的 SCID 小鼠的系统性弥漫大 B 细胞淋巴瘤模型中,可显著延长生存期,并降低肿瘤负荷。

Animal Model: BALB/cAJcl-nu/nu (6-week-old male; subcutaneously implanted with CCRF-CEM cells)
Dosage: 6.3 mg/kg; 12.5 mg/kg; 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.v.; weekly; 3 weeks
Result: Reduced mean tumor volume significantly compared to vehicle control (P < 0.05).
Achieved T/C ratios of 35%, 20%, 10%, 1%, and 0% for 6.3, 12.5, 25, 50, and 100 mg/kg, respectively.
Induced complete tumor regression at doses of 25, 50, and 100 mg/kg.
Decreased cullin1 neddylation, increased accumulation of CRL substrates CDT1, NRF2, and p-IκBα, and elevated levels of cleaved caspase-3 and cleaved PARP within 24 hours of administration.
Showed stronger, more durable reduction of NEDD8-cullin1 signal with increasing doses, with longer-lasting inhibition than MLN4924.
Caused no marked body weight loss.
Animal Model: C.B-17 SCID (6-week-old male; subcutaneously implanted with GRANTA-519 cells)
Dosage: 100 mg/kg
Administration: i.v.; weekly; 3 weeks; i.v.; twice weekly; 3 weeks
Result: Exerted statistically significant antitumor activity vs vehicle control at day 22 (P < 0.05).
Exceeded the antitumor activity of bortezomib and ibrutinib (P < 0.05).
Induced massive apoptosis in tumor tissue.
Caused no body weight loss exceeding 10% of initial weight.
Animal Model: BALB/cAJcl-nu/nu (6-week-old male; subcutaneously implanted with SU-CCS-1 cells)
Dosage: 100 mg/kg
Administration: i.v.; weekly; 3 weeks
Result: Exerted statistically significant antitumor activity vs vehicle control (P < 0.05), with marked tumor regression maintained throughout treatment.
Showed superior efficacy to doxorubicin hydrochloride, pazopanib, and MLN4924 (P < 0.05).
Induced cleaved PARP (apoptotic marker) within 4 hours post-administration, and large necrotic tumor areas by day 3.
Caused no body weight loss exceeding 10% of initial weight.
Animal Model: NOD-SCID (6-week-old female; subcutaneously implanted with LU5266 patient-derived cells)
Dosage: 75 mg/kg
Administration: i.v.; weekly; 3 weeks; i.v.; twice weekly; 3 weeks
Result: Exerted statistically significant antitumor activity vs vehicle control, with a majority of mice achieving complete tumor regression in both treatment groups.
Maintained tumor growth inhibition beyond 7 weeks.
Showed superior efficacy to cisplatin and etoposide (P < 0.05).
Caused no body weight loss exceeding 10% of initial weight.
Animal Model: SCID (6-week-old; systemically implanted via tail vein with 1×107 TMD8-Luc luciferase-expressing cells; treatment initiated 11 days post-transplantation)
Dosage: 100 mg/kg
Administration: i.v.; on days 1, 4, 8, 11 of each 21-day cycle; 8 cycles
Result: Prolonged survival time significantly compared to vehicle control, with median survival time>159 days and an increase in life span of 174%.
Reduced mean relative photon value (tumor burden index) significantly compared to vehicle control.
性状 固体
颜色 Light yellow to khaki

化学信息

分子量 542.97
分子式 C21H24ClFN6O6S
CAS No. 1848959-11-4

储存&溶解度

体内实验配方
30% PEG300+70% Saline: 5 mg/mL (9.21 mM)
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (184.17 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 5 mg/mL (9.21 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM1.8417 mL9.2086 mL18.4172 mL46.0431 mL
5 mM0.3683 mL1.8417 mL3.6834 mL9.2086 mL
DMSO10 mM0.1842 mL0.9209 mL1.8417 mL4.6043 mL
15 mM0.1228 mL0.6139 mL1.2278 mL3.0695 mL
20 mM0.0921 mL0.4604 mL0.9209 mL2.3022 mL
25 mM0.0737 mL0.3683 mL0.7367 mL1.8417 mL
30 mM0.0614 mL0.3070 mL0.6139 mL1.5348 mL
40 mM0.0460 mL0.2302 mL0.4604 mL1.1511 mL
50 mM0.0368 mL0.1842 mL0.3683 mL0.9209 mL
60 mM0.0307 mL0.1535 mL0.3070 mL0.7674 mL
80 mM0.0230 mL0.1151 mL0.2302 mL0.5755 mL
100 mM0.0184 mL0.0921 mL0.1842 mL0.4604 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础